Coverage includes:

• Stem cell models for drug screening
• Stem cells for toxicity assessment
• Stem cells as novel drug targets
• Cancer stem cells
• Role of stem cells in big pharma
• High-content screening of stem cells 

Distinguished Faculty:

Paul. D. Andrews, Ph.D., Senior Scientist, Stem Cell Programme, Drug Discovery Unit, College of Life Sciences, University of Dundee

Joshua E. Babiarz, Ph.D., Principal Scientist, Non-Clinical Safety, F. Hoffmann-La Roche, Ltd.

Peter Chu, Ph.D., Scientist, Discovery Cancer Therapeutics Group, Biogen Idec, Inc.

Brent Cochran, Ph.D., Principle Investigator, Department of Physiology, Tufts University School of Medicine

Davide Danovi, M.D., Ph.D., Neural Stem Cells Group, UCL Cancer Institute, University College London

Hakim Djaballah, Ph.D., Director, HTS Core Facility, Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center

Jennie Mather, Ph.D., Senior Vice President, Stem Cell Research, MacroGenics

William Matsui, M.D., Associate Professor, Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine

Yaping Liu, Ph.D., Senior Research Biologist, Automated Biotechnology, Merck Research Labs

Peter Sartipy, Ph.D., Senior Principal Scientist, Project Manager, Cellartis AB

Sanjeev Satyal, Ph.D., Director, Cancer Biology, OncoMed

Jan M. Van Tornout, M.D., M.Sc., Group Director & Lead EDT #2, Discovery Medicine Oncology/Immunology, Bristol-Myers Squibb Co.

Stephen Wong, Ph.D., Chair, Professor and Director, Center for Bioengineering and Informatics, The Methodist Hospital Research Institute, Weill Cornell Medical College

Xianmin Zeng, Ph.D., Associate Professor and Director, Laboratory for Stem Cells and Aging, Buck Institute

For more information, please contact:
Julia Boguslavsky, Executive Director, Conferences
E-mail: juliab@healthtech.com  

For sponsorship information, please contact:
Carol Dinerstein, Business Development
Phone: 781-972-5471; E-mail: dinerstein@healthtech.com